Definition
Pro-resolving mediators are endogenous signaling molecules that act as “stop signals” to terminate an inflammatory reaction when no longer needed to promote the return to a normal tissue state (Serhan 2014). This resolution of inflammation is achieved through both anti-inflammation and an active pro-resolution. The anti-inflammatory actions during the resolution of inflammation include counter-regulating pro-inflammatory signals and limiting immune cell infiltration. At the same time, active pro-resolving actions lead to the apoptosis and efflux of inflammatory cells and the promotion of macrophage uptake mechanisms to clean up the site of inflammation. Hence, anti-inflammation and pro-resolution are not equivalent processes. While both processes aim to limit inflammation, the pro-resolving mediators activate specific receptors to promote processes that facilitate tissue repair and return to...
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arnardottir HH, Dalli J, Colas RA, Shinohara M, Serhan CN (2014) Aging delays resolution of acute inflammation in mice: reprogramming the host response with novel nano-proresolving medicines. J Immunol 193:4235–4244
Arnardottir HH, Dalli J, Norling LV, Colas RA, Perretti M, Serhan CN (2016) Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation. J Immunol 197:2362–2368
Bäck M, Powell WS, Dahlen SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, Rovati GE (2014) Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR review 7. Br J Pharmacol 171:3551–3574
Bäck M, Yurdagul A Jr, Tabas I, Oorni K, Kovanen PT (2019) Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol 16:389–406
Carracedo M, Artiach G, Arnardottir H, Bäck M (2019a) The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification. Semin Immunopathol 41:757–766
Carracedo M, Witasp A, Qureshi AR, Laguna-Fernandez A, Brismar T, Stenvinkel P, Bäck M (2019b) Chemerin inhibits vascular calcification through ChemR23 and is associated with lower coronary calcium in chronic kidney disease. J Intern Med 286:449–457
Chiang N, Shinohara M, Dalli J, Mirakaj V, Kibi M, Choi AM, Serhan CN (2013) Inhaled carbon monoxide accelerates resolution of inflammation via unique proresolving mediator-heme oxygenase-1 circuits. J Immunol 190:6378–6388
Chiang N, Libreros S, Norris PC, De La Rosa X, Serhan CN (2019) Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions. J Clin Invest 129:5294–5311
Dalli J, Colas RA, Arnardottir H, Serhan CN (2017) Vagal regulation of group 3 innate lymphoid cells and the immunoresolvent PCTR1 controls infection resolution. Immunity 46:92–105
Fredman G, Ozcan L, Spolitu S, Hellmann J, Spite M, Backs J, Tabas I (2014) Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway. Proc Natl Acad Sci U S A 111:14530–14535
Hansen TV, Vik A, Serhan CN (2018) The protectin family of specialized pro-resolving mediators: potent immunoresolvents enabling innovative approaches to target obesity and diabetes. Front Pharmacol 9:1582
Hanson J, Ferreiros N, Pirotte B, Geisslinger G, Offermanns S (2013) Heterologously expressed formyl peptide receptor 2 (FPR2/ALX) does not respond to lipoxin A(4). Biochem Pharmacol 85:1795–1802
Laguna-Fernandez A, Checa A, Carracedo M, Artiach G, Petri MH, Baumgartner R, Forteza MJ, Jiang X, Andonova T, Walker ME, Dalli J, Arnardottir H, Gistera A, Thul S, Wheelock CE, Paulsson-Berne G, Ketelhuth DFJ, Hansson GK, Bäck M (2018) ERV1/ChemR23 signaling protects against atherosclerosis by modifying oxidized low-density lipoprotein uptake and phagocytosis in macrophages. Circulation 138:1693–1705
Perretti M, D’acquisto F (2009) Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 9:62–70
Petri MH, Laguna-Fernandez A, Gonzalez-Diez M, Paulsson-Berne G, Hansson GK, BÄCK M (2015) The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability. Cardiovasc Res 105:65–74
Pirault J, Bäck M (2018) Lipoxin and resolvin receptors transducing the resolution of inflammation in cardiovascular disease. Front Pharmacol 9:1273
Serhan CN (2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature 510:92–101
Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM (2016) Resolution of inflammation: what controls its onset? Front Immunol 7:160
Thul S, Labat C, Temmar M, Benetos A, Bäck M (2017) Low salivary resolvin D1 to leukotriene B4 ratio predicts carotid intima media thickness: a novel biomarker of non-resolving vascular inflammation. Eur J Prev Cardiol 24:903–906
Wallace JL, Ianaro A, Flannigan KL, Cirino G (2015) Gaseous mediators in resolution of inflammation. Semin Immunol 27:227–233
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
Arnardottir, H., Bäck, M. (2021). Pro-resolving Mediators. In: Offermanns, S., Rosenthal, W. (eds) Encyclopedia of Molecular Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-030-57401-7_10037
Download citation
DOI: https://doi.org/10.1007/978-3-030-57401-7_10037
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-57400-0
Online ISBN: 978-3-030-57401-7
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences